Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials

References

• Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):1–9. doi:10.1016/S0140-6736(20)31286-1.
   PubMed Web of Science ®Google Scholar
• Silverberg JI. Comorbidities and the impact of atopic dermatitis. Ann Allergy Asthma Immunol. 2019;123(2):144–151. doi:10.1016/j.anai.2019.04.020.
   PubMed Web of Science ®Google Scholar
• Drucker AM, Wang AR, Li WQ, et al. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Investig Dermatol. 2017;137(1):26–30.
   PubMed Web of Science ®Google Scholar
• Bieber T, Straeter B. Off-label prescriptions for atopic dermatitis in Europe. Allergy. 2015;70:6–11.
   PubMed Web of Science ®Google Scholar
• Harrop J, Chinn S, Verlato G, et al. Eczema, atopy and allergen exposure in adults: a population-based study. Clin Exp Allergy. 2007;37(4):526–535. doi:10.1111/j.1365-2222.2007.02679.x.
   PubMed Web of Science ®Google Scholar
• Diepgen TL, Ofenloch R, Bruze M, et al. Prevalence of fragrance contact allergy in the general population of five European countries: a cross-sectional study. Br J Dermatol. 2015;173(6):1411–1419. doi:10.1111/bjd.14151.
   PubMedGoogle Scholar
• Sacotte R, Silverberg JI. Epidemiology of adult atopic dermatitis. Clin Dermatol. 2018;36(5):595–605. doi:10.1016/j.clindermatol.2018.05.007.
   PubMed Web of Science ®Google Scholar
• Saeki H, Tsunemi Y, Fujita H, et al. Prevalence of atopic dermatitis determined by clinical examination in Japanese adults. J Dermatol. 2006;33(11):817–819. doi:10.1111/j.1346-8138.2006.00187.x.
   PubMed Web of Science ®Google Scholar
• Weidinger S, Beck LA, Bieber T, et al. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. doi:10.1038/s41572-018-0001-z.
   PubMed Web of Science ®Google Scholar
• Lee HH, Patel KR, Singam V, et al. A systematic review and meta-analysis of the prevalence and phenotype of adult-onset atopic dermatitis. J Am Acad Dermatol. 2019;80(6):1526–1532 e7. doi:10.1016/j.jaad.2018.05.1241.
   PubMed Web of Science ®Google Scholar
• Laughter MA-O, Maymone MBC, Mashayekhi S, et al. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990–2017. Br J Dermatol. 2021;184(2):304–309.
   PubMed Web of Science ®Google Scholar
• Pompili M, Bonanni L, Gualtieri F, et al. Suicidal risks with psoriasis and atopic dermatitis: systematic review and meta-analysis. J Psychosom Res. 2021;141:110347.
   PubMed Web of Science ®Google Scholar
• Slattery M, Fau- Essex MJ, Essex M, et al. Depression, anxiety, and dermatologic quality of life in adolescents with atopic dermatitis. J Allergy Clin Immunol. 2011;128(3):668–671.
   PubMed Web of Science ®Google Scholar
• Narla S, Silverberg JI. The role of environmental exposures in atopic dermatitis. Curr Allergy Asthma Rep. 2020;20(12):74. doi:10.1007/s11882-020-00971-z.
   PubMed Web of Science ®Google Scholar
• Andersen L, Nyeland ME, Nyberg F. Increasing severity of atopic dermatitis is associated with a negative impact on work productivity among adults with atopic dermatitis in France, Germany, the U.K. and the U.S.A. Br J Dermatol. 2020;182(4):1007–1016.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema - part II: non-systemic treatments and treatment recommendations for special AE patient populations. J Eur Acad Dermatol Venereol. 2022;36(11):1904–1926. doi:10.1111/jdv.18429.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682. doi:10.1111/jdv.14891.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32(6):850–878. doi:10.1111/jdv.14888.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Christen-Zäch S, Taieb A, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34(12):2717–2744. doi:10.1111/jdv.16892.
   PubMed Web of Science ®Google Scholar
• Sidbury R, Kodama S. Atopic dermatitis guidelines: diagnosis, systemic therapy, and adjunctive care. Clin Dermatol. 2018;36(5):648–652. doi:10.1016/j.clindermatol.2018.05.008.
   PubMed Web of Science ®Google Scholar
• Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2022;21(1):21–40. doi:10.1038/s41573-021-00266-6.
   PubMed Web of Science ®Google Scholar
• Patrizi A, Costanzo A, Patruno C, et al. Unmet needs in atopic dermatitis management: an expert consensus. J Dermatolog Treat. 2022;33(5):2459–2465. 4 doi:10.1080/09546634.2021.1967267.
   PubMed Web of Science ®Google Scholar
• Ratnarajah KA-O, Le M, Muntyanu AA-OX, et al. Inhibition of IL-13: a new pathway for atopic dermatitis. J Cutan Med Surg. 2020;25:315–328.
   PubMed Web of Science ®Google Scholar
• Bieber T. Interleukin-13: targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75(1):54–62. doi:10.1111/all.13954.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Flohr C, Eichenfield LF, et al. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: a randomized, placebo-controlled phase II trial (TREBLE). J Am Acad Dermatol. 2018;78(5):863–871 e11. doi:10.1016/j.jaad.2018.01.017.
   PubMed Web of Science ®Google Scholar
• Ungar B, Garcet S, Gonzalez J, et al. An integrated model of atopic dermatitis biomarkers highlights the systemic nature of the disease. J Invest Dermatol. 2017;137(3):603–613. doi:10.1016/j.jid.2016.09.037.
   PubMed Web of Science ®Google Scholar
• Xiao S, Lu Z, Steinhoff M, et al. Innate immune regulates cutaneous sensory IL-13 receptor alpha 2 to promote atopic dermatitis. Brain Behav Immun. 2021;98:28–39. doi:10.1016/j.bbi.2021.08.211.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Guttman-Yassky E, Thaçi D, et al. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023;388(12):1080–1091. doi:10.1056/NEJMoa2206714.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338–351. doi:10.1016/j.jaad.2013.10.010.
   PubMed Web of Science ®Google Scholar
• Revolutionizing Atopic Dermatitis, 11–13 December 2021. Br J Dermatol. 2022;186(4):e135–e173.
   PubMed Web of Science ®Google Scholar
• Yosipovitch G. Revolutionizing atopic dermatitis, 11–13 December 2021. Br J Dermatol. 2022;186(4):e147.
   Web of Science ®Google Scholar
• Finlay AY, Khan GK. Dermatology life quality index (DLQI)–a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210–216. doi:10.1111/j.1365-2230.1994.tb01167.x.
   PubMed Web of Science ®Google Scholar
• Hongbo Y, Thomas CL, Harrison MA, et al. Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol. 2005;125(4):659–664. doi:10.1111/j.0022-202X.2005.23621.x.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Margolis DJ, Boguniewicz M, et al. Validation of five patient-reported outcomes for atopic dermatitis severity in adults. Br J Dermatol. 2020;182(1):104–111. doi:10.1111/bjd.18657.
   PubMed Web of Science ®Google Scholar
• Khilji FA, Gonzalez M, Finlay A. Clinical meaning of change in dermatology life quality index scores. Br J Dermatol. 2002;147:50.
   Google Scholar
• Basra MK, Salek MS, Camilleri L, et al. Determining the minimal clinically important difference and responsiveness of the dermatology life quality index (DLQI): further data. Dermatology. 2015;230(1):27–33. doi:10.1159/000365390.
   PubMed Web of Science ®Google Scholar
• Lio PA, Simpson EL, Han G, et al. Improvement in sleep and itch and enhanced quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a phase 3 trial of baricitinib therapy. J Dermatolog Treat. 2022;33(4):2057–2062. doi:10.1080/09546634.2021.1914308.
   PubMed Web of Science ®Google Scholar
• Koszoru K, Borza J, Gulacsi L, et al. Quality of life in patients with atopic dermatitis. Cutis. 2019;104(3):174–177.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Blauvelt A, Eichenfield LF, et al. Efficacy and safety of lebrikizumab, a high-Affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase 2b randomized clinical trial. JAMA Dermatol. 2020;156(4):411–420. doi:10.1001/jamadermatol.2020.0079.
   PubMed Web of Science ®Google Scholar